Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.26, read 2026-10-17
Ethical does not pass the values gate
Price200.97 USD
Fair value137.97
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-09-03Read Accumulation173.96+15.5% to today ✓Markdown gives way to Accumulation after a 28% rise in 9 weeks
2026-07-02Read Markdown135.53+48.3% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Palantir Technologies holds its Accumulation at $200.97. The statistical read favours the sellers, held for 30 days.
As held on the ledger · 2026-10-14
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 30 days
Price at the screen
$200.97
Valuation
173.25 trailing · 85.73 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.60
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.58%
Below 33%
Interest-bearing debt is just 2.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
64.64%
Below 33%
Interest-bearing cash and securities are 64.6% of assets, above the one-third limit.
Fail
Receivables
27.71%
Below 49%
Money owed to the company is 27.7% of assets, under the 49% limit.
Pass
Revenue purity
5.12%
Below 5%
5.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Palantir Technologies's business is fine, but its cash and interest-bearing securities are about 65% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-20. It updates when the underlying figures move, and past reads are kept below.
The Conscience Overlay
Conscience flag · AFSC Investigate, Don’t Buy Into Occupation, Who Profits Corporate Database
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate / Don’t Buy Into Occupation / Who Profits Corporate Database — category: Corporate Complicity Report / Annex 2 Company List. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $137.97 fair value estimate, strong competitive moat, 92.80% revenue growth.
Fair value range in USD, drawn from the 2026-10-14 screen. The gold marker is the market price at the same screen. The price runs 31.3% above the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +7% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-14 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Palantir's Ethical Woes Despite High Praise
Palantir Technologies, often discussed as a tech darling, is the go-to for the intelligence community's counterterrorism efforts. Imagine a digital detective kit that helps solve complex crimes - that's Palantir. But the reason we're passing on it? Not the business fundamentals, but ethical considerations and high valuation. Despite its 93% revenue growth and robust profit margin of 49%, Palantir fails our ethical screen due to its interest-bearing securities. Why it stands out would otherwise be its strong moat and high ROE of 38%, which speaks to its profitability and efficiency.
However, at a price of $173.96 and a forward P/E of 75.2x, the market is pricing in an extremely high future earnings expectation. In comparison, our fair value is significantly lower at $132.09, indicating a margin of safety of -24%. Risk sits in the high valuation and the ethical failings - a double whammy that makes us cautious. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PLTR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-18Accumulation$200.97+6.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184.
2026-10-11Accumulation$189.67+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184.
2026-10-02Accumulation$189.67+9.0%Entry 12
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 41.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184.
2026-08-03Markdown$122.92+0.0%Entry 10
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-02Markdown$122.92+0.0%Entry 9
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-01Markdown$122.92+0.0%Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-31Markdown$122.92+0.0%Entry 7
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-30Markdown$122.92+0.0%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-28Markdown$122.92+0.0%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
